Key Highlights
- Oversubscribed Series A funding of $18.75 million led by Arboretum Ventures.
- Funding to advance the development of DOT microstimulator, a brain pacemaker for mental health disorders.
- Focus on treatment-resistant depression (TRD), a major depressive disorder subset.
Source: Business Wire
Notable Quotes
- “Minimally-invasive bioelectronics are the future of mental health treatment,” – Jacob Robinson, CEO & Founder at Motif Neurotech
- “We believe Motif’s device will greatly improve the quality of life for patients who have been diagnosed with difficult to treat mental health disorders, including TRD,” – Tom Shehab, Managing Partner at Arboretum Ventures
SoH's Take
Motif Neurotech’s impressive Series A funding round marks a significant leap forward in the field of mental health treatment. With the development of the DOT microstimulator, a potential game-changer for treating TRD, Motif is addressing a critical gap in current treatment options. Their focus on a minimally-invasive, outpatient procedure underscores a commitment to patient accessibility and convenience, which could revolutionize the approach to mental health care. The involvement of seasoned investors and industry veterans on their board signifies confidence in their approach and technology. This funding not only represents a substantial financial milestone but also a beacon of hope for those suffering from treatment-resistant mental health disorders.
